AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models

Inflammatory breast cancer (IBC): clues for targeted therapies

(2013) Sandra V. Fernandez et al.   BREAST CANCER RESEARCH AND TREATMENT

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

(2013) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of epidermal growth factor receptor in breast cancer

(2012) Hiroko Masuda et al.   BREAST CANCER RESEARCH AND TREATMENT

Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer

(2011) J. Li et al.   ONCOLOGIST

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

(2010) S. Dawood et al.   ANNALS OF ONCOLOGY

Epidermal Growth Factor Receptor in Triple-Negative and Basal-Like Breast Cancer

(2010) Monika L. Burness et al.   CANCER JOURNAL

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

(2010) D. M. Hickinson et al.   CLINICAL CANCER RESEARCH

Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Lapatinib Plus Paclitaxel in Patients With Inflammatory Breast Cancer

(2010) Hamouda Boussen et al.   JOURNAL OF CLINICAL ONCOLOGY

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer

(2009) D. Zhang et al.   CLINICAL CANCER RESEARCH

Molecular targets for treatment of inflammatory breast cancer

(2009) Hideko Yamauchi et al.   Nature Reviews Clinical Oncology

Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy

(2008) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells

(2008) D. Zhang et al.   MOLECULAR CANCER THERAPEUTICS